EUVIMEDEUVIMED entdecken
Multizentrische Studie

Possible rapid reduction of anti‐ RBD antibody titre after SARS ‐ CoV ‐2 mRNA vaccination in pregnant women: Multicentre prospective study

Mamiko Ohta, Kaoru Kawasaki iD, Rumiko Yamamoto, Keisuke Ishii iD, Kazutoshi Nakano iD, Shinobu Akada, Kunihiko Doh, Masao Shimaoka, Hiroshi Ota, Kaori Moriuchi, Reona Shiro, Yoshie Yo und 3 weitere

Journal of Obstetrics and Gynaecology Research · 2025

DOI: 10.1111/jog.16150 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Obstetrics and Gynaecology Research, 2025. Verfasst von Mamiko Ohta und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynaecology, Kindai University Faculty of Medicine, Osaka, Japan. Hauptthemen laut MEDLINE: Antibodies, Viral, COVID-19, COVID-19 Vaccines, SARS-CoV-2. Die Arbeit nennt 29 Literaturangaben. Gefördert von: All-Kindai University support project against COVID-19.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Pregnant women are at increased risk for severe illness associated with coronavirus disease 2019 (COVID‐19) compared to nonpregnant women. The aim of this multicenter prospective study was to assess the current COVID‐19 vaccination status of pregnant women in the southern Osaka district and to compare their antibody titers with those of nonpregnant women.

Methods

Serum antibody titers of anti‐NCP antibodies (antibodies against the SARS‐CoV‐2 nucleocapsid) and anti‐RBD antibodies (the receptor binding domain of the S1 subunit of the spike protein) were evaluated in 753 pregnant women at 34–35 weeks of gestation from October 2021 to March 2022. Anti‐RBD antibody titre was also investigated in 1003 health care workers at Kindai University hospital 3 and 6 months after a second dose of the vaccine from March 2021 to April 2021. 519 (68.9%) pregnant women were vaccinated during pregnancy, of whom 497 (95.8%) received two doses.

Results

The COVID‐19 infection rate calculated from the number of pregnant women with a positive anti‐NCP antibody titre or with confirmed diagnosis was 5.1% (12/234) in the unvaccinated and 3.5% (18/519) in the vaccinated. The estimated half‐life calculated from anti‐RBD antibody titers and the number of days between vaccination and antibody testing was 39.9 days. The antibody titre and half‐life in pregnant women were significantly lower and shorter than in nonpregnant women aged 20–39 years (109.4 days).

Conclusion

Our study showed that pregnant women may have lower vaccine‐acquired COVID‐19 immunity than nonpregnant women.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, ViralCOVID-19COVID-19 VaccinesSARS-CoV-2HumansFemalePregnancyAdultProspective StudiesPregnancy Complications, InfectiousVaccinationYoung AdultSpike Glycoprotein, CoronavirusJapan

Stichwörter der Autor:innen

COVID‐19antibodiescoronavirus disease 2019pregnancyvaccination

Substanzen

Antibodies, ViralCOVID-19 VaccinesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2

Autor:innen und Institutionen

  • Department of Obstetrics and Gynaecology, Kindai University Faculty of Medicine, Osaka, Japan.
  • Department of Maternal Fetal Medicine, Osaka Women's and Children's Hospital, Osaka, Japan.
  • Department of Obstetrics and Gynaecology, Osaka Habikino Medical Centre, Osaka, Japan.
  • Department of Obstetrics and Gynaecology, PL Hospital, Osaka, Japan.
  • Department of Obstetrics and Gynaecology, Saiseikai Tondabayashi Hospital, Osaka, Japan.
  • Department of Obstetrics and Gynaecology, National Hospital Organization Osaka Minami Medical Centre, Osaka, Japan.

ORCID-Profile: Kaoru Kawasaki, Keisuke Ishii, Kazutoshi Nakano

Förderung

  • All-Kindai University support project against COVID-19

Zitieren

APA

Ohta, M., Kawasaki, K., Yamamoto, R., Ishii, K., Nakano, K., Akada, S., Doh, K., Shimaoka, M., Ota, H., Moriuchi, K., Shiro, R., Yo, Y., Yoshida, K., Tohda, Y., & Matsumura, N. (2025). Possible rapid reduction of anti‐ RBD antibody titre after SARS ‐ CoV ‐2 mRNA vaccination in pregnant women: Multicentre prospective study. Journal of Obstetrics and Gynaecology Research. https://doi.org/10.1111/jog.16150

Vancouver

Ohta M, Kawasaki K, Yamamoto R, Ishii K, Nakano K, Akada S, et al. Possible rapid reduction of anti‐ RBD antibody titre after SARS ‐ CoV ‐2 mRNA vaccination in pregnant women: Multicentre prospective study. Journal of Obstetrics and Gynaecology Research. 2025. doi:10.1111/jog.16150

BibTeX
@article{Ohta2025,
  author = {Ohta, Mamiko and Kawasaki, Kaoru and Yamamoto, Rumiko and Ishii, Keisuke and Nakano, Kazutoshi and Akada, Shinobu and Doh, Kunihiko and Shimaoka, Masao and Ota, Hiroshi and Moriuchi, Kaori and Shiro, Reona and Yo, Yoshie and Yoshida, Koichiro and Tohda, Yuji and Matsumura, Noriomi},
  title = {Possible rapid reduction of anti‐ RBD antibody titre after SARS ‐ CoV ‐2 mRNA vaccination in pregnant women: Multicentre prospective study},
  journal = {Journal of Obstetrics and Gynaecology Research},
  year = {2025},
  doi = {10.1111/jog.16150}
}
Kostenlos starten →